

Fiducian Growth Managed Shares Portfolio



Monthly Report - February 2024

Portfolio performance

	1 m	3 mths	6 mths	1 yr	2yrs	3yrs	4yrs	5yrs	7yrs	9yrs	10yrs
Total Portfolio Return	8.7%	17.0%	8.1%	15.3%	11.7%	8.7%	12.5%	12.8%	14.2%	12.7%	12.8%
Income	0.2%	0.2%	0.7%	1.7%	1.9%	1.9%	1.8%	2.0%	2.2%	2.6%	2.7%
S&P/ASX 100 Accumulation Index	0.9%	9.4%	7.5%	10.8%	9.7%	10.1%	9.0%	9.2%	8.9%	7.4%	8.2%

Note: Portfolio performance as set out in the table above is a notional value only. The total return calculation assumes re-investment of all dividends and rebalancing of the portfolio to equal stock weightings after each stock change. In practice, each investor's portfolio is distinct with its own price and return history, while dividends are fully distributed and not re-invested and rebalancing occurs only intermittently. Returns over a year are annualised and since 1 July 2017 have been net of an investment management fee of 0.4% per annum.

Portfolio commentary

The portfolio gained 8.7% in February, which was above the benchmark return (ASX 100 index) of 0.9%. Stocks within the portfolio are well-diversified, growth-oriented blue-chips and as such, the portfolio could be expected to do particularly well in periods of stronger economic growth but could underperform the index in periods of slower growth, which tend to favour more defensive portfolios.

The broad Australian share market (ASX200 index) rose by 0.8% during the month. Most companies reported financial results for the period ending 31 December 2023. For many companies, expenses have been growing faster than revenue. Over calendar year 2023, expenses increased by 6%, compared with revenue growth of only 3%. These challenging conditions had generally been anticipated, with approximately two-thirds of companies reporting results that were either in-line with, or above, market expectations.

The top contributors to performance over the month were Wisetech Global (+29.4%), NextDC (+25.9%) and Pilbara Minerals (+18.3%). Wisetech announced revenues had been growing above expectations, and that strong cost control had also improved profits. NextDC continues to benefit from growing demand for data, with the company reporting a 31% increase in revenue over the last 12 months. Pilbara Minerals benefited from a recovery in the lithium price during the month.

The main detractors from performance during the month were Santos (-6.4%) and CSL (-5.1%). Santos announced that discussions with Woodside Energy regarding a potential merger had come to an end. CSL reported that trial results for a cardiovascular disease treatment had been unsuccessful.

Three changes were made to the portfolio during the month. Telix Pharmaceuticals, ProMedicus and Neuren Pharma were added to the portfolio. South32, Mineral Resources and Altium were removed. Telix has developed a number of radiopharmaceutical therapies that have applications in treating cancer and rare diseases. Pro Medicus provides advanced healthcare imaging software. Neuren is a pharmaceutical company that is developing treatments for a range of neurological disorders.


As at the end of February, the portfolio is forecast to provide investors with a prospective yield of 1.3% for the 2024-25 financial year, before the consideration of franking credits.

Portfolio holdings

Shares	P/E	Yield
Neuren Pharmaceuticals	68.2	0.0%
Cochlear	52.7	1.4%
Pilbara Minerals	32.3	1.0%
CSL	27.4	1.7%
NextDC		0.0%
Beach Energy	5.9	6.3%
Telix Pharmaceuticals	40.2	0.0%
Pro Medicus	105.1	0.5%
REA Group	47.0	1.2%
Aristocrat Leisure	20.3	1.7%
Xero	79.1	0.0%
WiseTech Global	85.1	0.2%
Worley	18.4	3.5%
Santos	11.2	4.5%
Average	48.5	1.3%

FY25 estimated price to earnings ratios and yields at end February 2024
Source: www.marketscreener.com

Portfolio performance



Fiducian Investment Management Services Limited

Issued by Fiducian Investment Management Services Limited ABN 28 602 441 814 AFS Licence number 468211. This document provides general information only. It does not have regard to your objectives, financial situation or needs. We recommend that you seek financial planning advice, and consider whether this investment is appropriate to your objectives, financial situation and needs before making any investment decision.

The information has been compiled from sources considered reliable, but is not guaranteed. Past performance is not indicative of future performance and we do not guarantee the performance of the Fund or any specific rate of return. Potential investors should also obtain and consider the relevant Target Market Determination (TMD) and Product Disclosure Statement (PDS) (available from your financial adviser and via fiducian.com.au) before making a decision about whether to acquire or continue to hold any financial product.